DORA AGUILAR: Open Payments
NPI 1659672368 · SPRING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,591 in 86 payments from 23 companies in 2025. Trend: 2023 $2,043 · 2024 $1,651 · 2025 $1,591
Food & beverage: $1,591
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $409 |
| ABBVIE INC. | 15 | $236 |
| Axsome Therapeutics, Inc. | 10 | $164 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $138 |
| Tris Pharma Inc | 4 | $73 |
| Amgen Inc. | 4 | $64 |
| Medtronic, Inc. | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Astellas Pharma US Inc | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
Products named: Wegovy, Kerendia, QULIPTA, VRAYLAR, Auvelity, Symbravo, Rybelsus, Dyanavel XR.
Industry payments across TX — which companies pay providers there.
